Clascoterone
Androgen Receptor Inhibitor — DERMATOLOGICALS
Also known as: breezula, CB-03-01, cortexolone 17alpha-propionate , winlevi
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Clascoterone is an ofp drug in the Androgen Receptor Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2020. Its mechanism of action is classified as Androgen Receptor Antagonists. DrugCentral lists 1 molecular target, including AR. Recorded indications include Acne vulgaris.
- Approval status: ofp (first approved 2020 by the FDA).
- Drug class: Androgen Receptor Inhibitor.
- Mechanism of action: Androgen Receptor Antagonists.
- Molecular targets: AR (1 listed in DrugCentral).
- Indications: Acne vulgaris.
- ATC code: D10AX06 (Other anti-acne preparations for topical use).
- Molecular formula: C24H34O5; molecular weight 402.53 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Acne vulgaris
Mechanism & targets
| Mechanism of action (MoA) | Androgen Receptor Antagonists |
|---|---|
| Established pharmacologic class | Androgen Receptor Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Androgen receptor | AR | antagonist | IC50 7.30 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-08-26 | FDA | — | CASSIOPEA SPA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D10AX06 | DERMATOLOGICALS › ANTI-ACNE PREPARATIONS › ANTI-ACNE PREPARATIONS FOR TOPICAL USE › Other anti-acne preparations for topical use |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Product storage error | 1493.4 |
| Product physical consistency issue | 292.1 |
| Product use complaint | 206.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Clascoterone is on its molecule page.
| Molecular formula | C24H34O5 |
|---|---|
| Molecular weight | 402.53 g/mol |
| CAS number | 19608-29-8 |
| InChIKey | GPNHMOZDMYNCPO-PDUMRIMRSA-N |
| PubChem CID | 11750009 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Clascoterone used for?
DrugCentral lists the following indications for Clascoterone: Acne vulgaris.
How does Clascoterone work?
Clascoterone is classified as Androgen Receptor Antagonists; its molecular targets in DrugCentral include AR (antagonist).
When was Clascoterone first approved?
Clascoterone was first approved by the FDA in 2020.
What drug class does Clascoterone belong to?
Clascoterone is in the Androgen Receptor Inhibitor class.
What is the chemical formula of Clascoterone?
Clascoterone has the molecular formula C24H34O5 and a molecular weight of 402.53 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5410 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3590187 — compound record and bioactivity
- PubChem CID 11750009 — chemical identifiers
- DrugBank DB12499 — drug record
- FDA UNII XN7MM8XG2M — substance identity
- DailyMed: FDA labels for Clascoterone — current prescribing information (label search)
- UniProt P10275 (AR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.